EUVIMEDEUVIMED entdecken
Open Access

ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer

Hirokazu Taniguchi iD, Subhamoy Chakraborty iD, Nobuyuki Takahashi iD, Avisek Banerjee iD, Rebecca Caeser, Yingqian A Zhan iD, Sam E Tischfield iD, Andrew Chow iD, Evelyn M Nguyen, Álvaro Quintanal Villalonga iD, Parvathy Manoj, Nisargbhai S Shah iD und 9 weitere

Science Advances · 27.09.2024 · 10 (39)

DOI: 10.1126/sciadv.ado4618 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 27.09.2024. Verfasst von Hirokazu Taniguchi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Ataxia Telangiectasia Mutated Proteins, Nucleotidyltransferases, Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with small-cell lung cancer (SCLC) have poor prognosis and typically experience only transient benefits from combined immune checkpoint blockade (ICB) and chemotherapy. Here, we show that inhibition of ataxia telangiectasia and rad3 related (ATR), the primary replication stress response activator, induces DNA damage–mediated micronuclei formation in SCLC models. ATR inhibition in SCLC activates the stimulator of interferon genes (STING)–mediated interferon signaling, recruits T cells, and augments the antitumor immune response of programmed death-ligand 1 (PD-L1) blockade in mouse models. We demonstrate that combined ATR and PD-L1 inhibition causes improved antitumor response than PD-L1 alone as the second-line treatment in SCLC. This study shows that targeting ATR up-regulates major histocompatibility class I expression in preclinical models and SCLC clinical samples collected from a first-in-class clinical trial of ATR inhibitor, berzosertib, with topotecan in patients with relapsed SCLC. Targeting ATR represents a transformative vulnerability of SCLC and is a complementary strategy to induce STING-interferon signaling–mediated immunogenicity in SCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ataxia Telangiectasia Mutated ProteinsNucleotidyltransferasesLung NeoplasmsSmall Cell Lung CarcinomaMembrane ProteinsSignal TransductionAnimalsHumansMiceCell Line, TumorInterferonsB7-H1 AntigenImmune Checkpoint InhibitorsTopotecanPyrazinesIsoxazolesSTING ProteinCyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase

Substanzen

Ataxia Telangiectasia Mutated ProteinsNucleotidyltransferasesMembrane ProteinsInterferonsB7-H1 AntigenImmune Checkpoint InhibitorsTopotecanPyrazinesIsoxazolesSTING1 protein, human

Autor:innen und Institutionen

  • Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA.
  • Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

ORCID-Profile: Hirokazu Taniguchi, Subhamoy Chakraborty, Nobuyuki Takahashi, Avisek Banerjee, Yingqian A Zhan, Sam E Tischfield, Andrew Chow, Álvaro Quintanal Villalonga, Nisargbhai S Shah, Samantha Rosario, Rui Qu, Elisa de Stanchina, Joseph Chan, Hiroshi Mukae, Anish Thomas, Charles M Rudin, Triparna Sen

Förderung

  • NCI NIH HHS

Zitieren

APA

Taniguchi, H., Chakraborty, S., Takahashi, N., Banerjee, A., Caeser, R., Zhan, Y. A., Tischfield, S. E., Chow, A., Nguyen, E. M., Villalonga, Á. Q., Manoj, P., Shah, N. S., Rosario, S., Hayatt, O., Qu, R., de Stanchina, E., Chan, J., Mukae, H., Thomas, A., …, & Sen, T. (2024). ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer. Science Advances, 10(39). https://doi.org/10.1126/sciadv.ado4618

Vancouver

Taniguchi H, Chakraborty S, Takahashi N, Banerjee A, Caeser R, Zhan YA, et al. ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer. Science Advances. 2024;10(39). doi:10.1126/sciadv.ado4618

BibTeX
@article{Taniguchi2024,
  author = {Taniguchi, Hirokazu and Chakraborty, Subhamoy and Takahashi, Nobuyuki and Banerjee, Avisek and Caeser, Rebecca and Zhan, Yingqian A and Tischfield, Sam E and Chow, Andrew and Nguyen, Evelyn M and Villalonga, Álvaro Quintanal and Manoj, Parvathy and Shah, Nisargbhai S and Rosario, Samantha and Hayatt, Omar and Qu, Rui and de Stanchina, Elisa and Chan, Joseph and Mukae, Hiroshi and Thomas, Anish and Rudin, Charles M and Sen, Triparna},
  title = {ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer},
  journal = {Science Advances},
  year = {2024},
  volume = {10},
  number = {39},
  doi = {10.1126/sciadv.ado4618}
}
Kostenlos starten →